ArticleThe Lancet. Global health2021
Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis.
Article in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 68 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Tracking the evolution of tuberculosis research priorities in Africa: a longitudinal bibliometric analysis from 2003-2023.Frontiers in research metrics and analytics · 2026Pooled it
- Pooled it
- Socioeconomic impacts of airborne and droplet-borne infectious diseases on industries: a systematic review.BMC infectious diseases · 2024Pooled it
- Association Between Cytomegalovirus Infection and Tuberculosis Disease: A Systematic Review and Meta-Analysis of Epidemiological Studies.The Journal of infectious diseases · 2023Pooled it
- Evaluation of the tuberculosis notification impact from an intermediary-facilitated public-private mix intervention in Viet Nam: A population-level quasi-experimental study.PLoS medicine · 2026Article
- Global, regional, and national economic value of reducing amenable tuberculosis mortality.Infectious Disease Modelling · 2026Article
- Article
- Risk of incident tuberculosis after severe COVID-19: a nationwide cohort study.Nature communications · 2026Article
- Current perspectives on avian tuberculosis in domestic and wild birds: Molecular diagnostics, genomic surveillance, and vaccination challenges.Open veterinary journal · 2026Review
- Zoonotic Tuberculosis as a One Health Challenge: Global Evidence, Transmission Dynamics, and Policy Gaps in Indonesia.Veterinary sciences · 2026Review
- Impact of the COVID-19 Pandemic on Vaccine-Preventable Diseases in Mexico: A Time Series Analysis (2014-2024).Epidemiologia (Basel, Switzerland) · 2026Article
- Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes.Nature microbiology · 2026Article
- Photodynamic inactivation of Mycobacterium tuberculosis by broad-spectrum visible light.Applied microbiology and biotechnology · 2026Article
- Multi-level determinants of tuberculosis treatment completion in rural Uganda: A cross-sectional study.PloS one · 2026Article
- The Global Economic Burden of Tuberculosis: Regional Disparities and Implications.Open forum infectious diseases · 2026Article
- Assessing the impact of Enhanced-Case-Finding on tuberculosis case notifications and transmission in The Gambia using epidemiological and phylodynamic approaches.Open research Europe · 2026Article
- Impact of tuberculosis on median survival time and years of potential life lost in patients: A scoping review.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Review
- Prevalence and treatment outcomes of latent tuberculosis infection among older patients with chronic obstructive pulmonary disease in an area with intermediate tuberculosis burden.Emerging microbes & infections · 2025Article
- Prevalence of Tuberculosis in Central Asia and Southern Caucasus: A Systematic Literature Review.Diagnostics (Basel, Switzerland) · 2025Review
- AveloMask, a novel breath aerosol collection kit for airborneJournal of clinical microbiology · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
backgroundThe tuberculosis targets for the UN Sustainable Development Goals (SDGs) call for a 90% reduction in tuberculosis deaths by 2030, compared with 2015, but meeting this target now seems highly improbable. To assess the economic impact of not meeting the target until 2045, we estimated full-income losses in 120 countries, including those due to excess deaths resulting from COVID-19-related disruptions to tuberculosis services, for the period 2020-50.
methodsAnnual mortality risk changes at each age in each year from 2020 to 2050 were estimated for 120 countries. This risk change was then converted to full-income risk by calculating a population-level mortality risk change and multiplying it by the value of a statistical life-year in each country and year. As a comparator, we assumed that current rates of tuberculosis continue to decline through the period of analysis. We calculated the full-income losses, and mean life expectancy losses per person, at birth and at age 35 years, under scenarios in which the SDG targets are met in 2030 and in 2045. We defined the cost of inaction as the difference in full-income losses and tuberculosis mortality between these two scenarios.
findingsFrom 2020 to 2050, based on the current annual decrease in tuberculosis deaths of 2%, 31·8 million tuberculosis deaths (95% uncertainty interval 25·2 million-39·5 million) are estimated to occur, corresponding to an economic loss of US$17·5 trillion (14·9 trillion-20·4 trillion). If the SDG tuberculosis mortality target is met in 2030, 23·8 million tuberculosis deaths (18·9 million-29·5 million) and $13·1 trillion (11·2 trillion-15·3 trillion) in economic losses can be avoided. If the target is met in 2045, 18·1 million tuberculosis deaths (14·3 million-22·4 million) and $10·2 trillion (8·7 trillion-11·8 trillion) can be avoided. The cost of inaction of not meeting the SDG tuberculosis mortality target until 2045 (vs 2030) is, therefore, 5·7 million tuberculosis deaths (5·1 million-8·1 million) and $3·0 trillion (2·5 trillion-3·5 trillion) in economic losses. COVID-19-related disruptions add $290·3 billion (260·2 billion-570·1 billion) to this cost.
interpretationFailure to achieve the SDG tuberculosis mortality target by 2030 will lead to profound economic and health losses. The effects of delay will be greatest in sub-Saharan Africa. Affected countries, donor nations, and the private sector should redouble efforts to finance tuberculosis programmes and research because the economic dividend of such strategies is likely to be substantial.
fundingNone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.